Tricuspid regurgitation risk factors: Difference between revisions

Jump to navigation Jump to search
 
(6 intermediate revisions by the same user not shown)
Line 4: Line 4:
{{CMG}}; {{AE}}  
{{CMG}}; {{AE}}  
==Overview==
==Overview==
There are no established risk factors for [disease name].
Common risk factors in the development of [[tricuspid regurgitation]] include [[Infection|infections]], [[endocarditis]], [[ebstein anomaly]], [[tricuspid valve prolapse]], [[carcinoid]], [[Papillary muscle dysfunction|papillary muscle]] dysfunction and [[medications]]. Most cases of significant [[tricuspid regurgitation]] are due to [[tricuspid]] annular dilation and leaflet tethering secondary to right [[ventricular]] remodeling from volume and/or pressure overload.
 
OR
 
The most potent risk factor in the development of [disease name] is [risk factor 1]. Other risk factors include [risk factor 2], [risk factor 3], and [risk factor 4].
 
OR
 
Common risk factors in the development of [[tricuspid regurgitation]] include infections, endocarditis, ebstein anomaly, tricuspid valve prolapse, carcinoid, papillary muscle dysfunction and medications. Most cases of significant [[tricuspid regurgitation]] are due to [[tricuspid]] annular dilation and leaflet tethering secondary to right [[ventricular]] remodeling from volume and/or pressure overload.
 
Common risk factors in the development of [disease name] may be occupational, environmental, genetic, and viral.


==Risk Factors==
==Risk Factors==
There are no established risk factors for [disease name].
===Common Risk Factors===


OR
*Common risk factors in the development of [[tricuspid regurgitation]] include:<ref name="pmid17400120">{{cite journal| author=Mutlak D, Lessick J, Reisner SA, Aronson D, Dabbah S, Agmon Y| title=Echocardiography-based spectrum of severe tricuspid regurgitation: the frequency of apparently idiopathic tricuspid regurgitation. | journal=J Am Soc Echocardiogr | year= 2007 | volume= 20 | issue= 4 | pages= 405-8 | pmid=17400120 | doi=10.1016/j.echo.2006.09.013 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17400120  }}</ref><ref name="pmid18222317">{{cite journal| author=Shah PM, Raney AA| title=Tricuspid valve disease. | journal=Curr Probl Cardiol | year= 2008 | volume= 33 | issue= 2 | pages= 47-84 | pmid=18222317 | doi=10.1016/j.cpcardiol.2007.10.004 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18222317  }}</ref><ref name="pmid3536106">{{cite journal| author=Waller BF| title=Etiology of pure tricuspid regurgitation. | journal=Cardiovasc Clin | year= 1987 | volume= 17 | issue= 2 | pages= 53-95 | pmid=3536106 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=3536106  }}</ref>
 
**[[Rheumatic heart disease]]
The most potent risk factor in the development of [disease name] is [risk factor 1]. Other risk factors include [risk factor 2], [risk factor 3], and [risk factor 4].
**[[Endocarditis]] is a common risk factor in developing [[tricuspid regurgitation]] due to the following:
 
***[[Alcoholism]]
OR
***[[Intravenous drug use]]
 
***[[Cardiac|Cardiac tumours]]
Common risk factors in the development of [disease name] include [risk factor 1], [risk factor 2], [risk factor 3], and [risk factor 4].
***Indwelling [[Catheter|catheters]] which might get infected
===Common Risk Factors===
***[[Burn|Burns]] when extensive
*Common risk factors in the development of [disease name] may be occupational, environmental, genetic, and viral.
**[[Tricuspid valve prolapse]]
*Common risk factors in the development of [[tricuspid regurgitation]] include:
**[[Papillary muscle dysfunction]]
**Rheumatic heart disease
**[[Right ventricle|RV]] dilatation
**Endocarditis is a common risk factor in developing tricuspid regurgitation due to the following:
**[[Trauma]] which includes:
***Alcoholism
***[[Right ventricle|Right ventricular]] [[endomyocardial]] [[biopsy]]
***Intravenous drug use
***Blunt chest wall [[trauma]] like stab wounds and projectiles
***Cardiac tumours  
***Indwelling catheters which might get infected
***Burns when extensive
**Tricuspid valve prolapse
**Papillary muscle dysfunction
**RV dilatation


===Less Common Risk Factors===
===Less Common Risk Factors===
*Less common risk factors in the development of [[tricuspid regurgitation]] include:
*Less common [[Risk factor|risk factors]] in the development of [[tricuspid regurgitation]] include:
**Pregnant mothers who are using lithium are at a risk for developing ebstein anomaly
**Pregnant mothers who are using lithium are at a risk for developing ebstein anomaly
**Connective-tissue diseases
**Connective-tissue diseases
**Medications which include:<ref name="pmid15277624">{{cite journal| author=Baseman DG, O'Suilleabhain PE, Reimold SC, Laskar SR, Baseman JG, Dewey RB| title=Pergolide use in Parkinson disease is associated with cardiac valve regurgitation. | journal=Neurology | year= 2004 | volume= 63 | issue= 2 | pages= 301-4 | pmid=15277624 | doi=10.1212/01.wnl.0000129842.49926.07 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15277624  }}</ref>
**Medications which include:<ref name="pmid15277624">{{cite journal| author=Baseman DG, O'Suilleabhain PE, Reimold SC, Laskar SR, Baseman JG, Dewey RB| title=Pergolide use in Parkinson disease is associated with cardiac valve regurgitation. | journal=Neurology | year= 2004 | volume= 63 | issue= 2 | pages= 301-4 | pmid=15277624 | doi=10.1212/01.wnl.0000129842.49926.07 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15277624 }}</ref><ref name="pmid12479512">{{cite journal| author=Pritchett AM, Morrison JF, Edwards WD, Schaff HV, Connolly HM, Espinosa RE| title=Valvular heart disease in patients taking pergolide. | journal=Mayo Clin Proc | year= 2002 | volume= 77 | issue= 12 | pages= 1280-6 | pmid=12479512 | doi=10.4065/77.12.1280 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12479512 }}</ref>
***Fenfluramine
***Fenfluramine
***Phentermine  
***Phentermine  

Latest revision as of 13:57, 21 April 2020

Tricuspid Regurgitation Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Tricuspid Regurgitation from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

Stages

History and Symptoms

Physical Examination

Laboratory Findings

Echocardiography

Chest X Ray

Electrocardiogram

Cardiac Stress Test

Cardiac MRI

Cardiac Catheterization

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical therapy

Surgery

Primary Prevention

Secondary Prevention

Case Studies

Case #1

Tricuspid regurgitation risk factors On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Tricuspid regurgitation risk factors

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA onTricuspid regurgitation risk factors

CDC on Tricuspid regurgitation risk factors

Tricuspid regurgitation risk factors in the news

Blogs on Tricuspid regurgitation risk factors

Directions to Hospitals Treating Tricuspid regurgitation

Risk calculators and risk factors for Tricuspid regurgitation risk factors

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

Common risk factors in the development of tricuspid regurgitation include infections, endocarditis, ebstein anomaly, tricuspid valve prolapse, carcinoid, papillary muscle dysfunction and medications. Most cases of significant tricuspid regurgitation are due to tricuspid annular dilation and leaflet tethering secondary to right ventricular remodeling from volume and/or pressure overload.

Risk Factors

Common Risk Factors

Less Common Risk Factors

  • Less common risk factors in the development of tricuspid regurgitation include:
    • Pregnant mothers who are using lithium are at a risk for developing ebstein anomaly
    • Connective-tissue diseases
    • Medications which include:[4][5]
      • Fenfluramine
      • Phentermine
      • Pergolide

References

  1. Mutlak D, Lessick J, Reisner SA, Aronson D, Dabbah S, Agmon Y (2007). "Echocardiography-based spectrum of severe tricuspid regurgitation: the frequency of apparently idiopathic tricuspid regurgitation". J Am Soc Echocardiogr. 20 (4): 405–8. doi:10.1016/j.echo.2006.09.013. PMID 17400120.
  2. Shah PM, Raney AA (2008). "Tricuspid valve disease". Curr Probl Cardiol. 33 (2): 47–84. doi:10.1016/j.cpcardiol.2007.10.004. PMID 18222317.
  3. Waller BF (1987). "Etiology of pure tricuspid regurgitation". Cardiovasc Clin. 17 (2): 53–95. PMID 3536106.
  4. Baseman DG, O'Suilleabhain PE, Reimold SC, Laskar SR, Baseman JG, Dewey RB (2004). "Pergolide use in Parkinson disease is associated with cardiac valve regurgitation". Neurology. 63 (2): 301–4. doi:10.1212/01.wnl.0000129842.49926.07. PMID 15277624.
  5. Pritchett AM, Morrison JF, Edwards WD, Schaff HV, Connolly HM, Espinosa RE (2002). "Valvular heart disease in patients taking pergolide". Mayo Clin Proc. 77 (12): 1280–6. doi:10.4065/77.12.1280. PMID 12479512.

Template:WH Template:WS